HDAC6 and ovarian carcinoma: To develop a potential combination treatment strategy using HDAC6 inhibitors against ovarian cancer, 25278, one of the most potent compounds, was used for a preliminary test in combination with anticancer agents including paclitaxel (Taxol), bortezomib, cisplatin, and MK-2206 by the MTT assay in ES-2 cells.